{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:42:13Z","timestamp":1793893333365,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundacion Fero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108242","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:26:37Z","timestamp":1786735597000},"page":"108242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Homologous recombination deficiency testing implementation in the routine clinical setting: real-life experience and lessons learned"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1207-7614","authenticated-orcid":false,"given":"P.","family":"Romero-Lozano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"G\u00f3mez-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vila-Casades\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Onieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4792-0142","authenticated-orcid":false,"given":"N.","family":"Deltiempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-318X","authenticated-orcid":false,"given":"R.","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-0990","authenticated-orcid":false,"given":"P.","family":"Nuciforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Garcia-Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2888-6512","authenticated-orcid":false,"given":"A","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108242_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.esmoop.2026.108242_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108242_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability\u2013an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.esmoop.2026.108242_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2026.108242_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108242_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.108242_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib9","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2026.108242_bib10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib11","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib13","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib14","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancers","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108242_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib17","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib18","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib19","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102040","article-title":"Incorporating Parp-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II\/III randomized controlled trials","volume":"87","author":"Ruscito","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.108242_bib21","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/cancers14051132","article-title":"Toward more comprehensive homologous recombination deficiency assays in ovarian cancer, part 1: technical considerations","volume":"14","author":"Quesada","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.108242_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/cancers14041098","article-title":"Toward more comprehensive homologous recombination deficiency assays in ovarian cancer part 2: medical perspectives","volume":"14","author":"Quesada","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.108242_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.675972","article-title":"Homologous recombination deficiency assays in epithelial ovarian cancer: current status and future direction","volume":"11","author":"Chiang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.esmoop.2026.108242_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"key":"10.1016\/j.esmoop.2026.108242_bib27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108242_bib28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2026.108242_bib29","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108242_bib30","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108242_bib31","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41388-023-02839-8","article-title":"Shallow whole genome sequencing approach to detect homologous recombination deficiency in the PAOLA-1\/ENGOT-OV25 phase-III trial","volume":"42","author":"Callens","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2026.108242_bib32","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1093\/bioinformatics\/btaa261","article-title":"ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing","volume":"36","author":"Eeckhoutte","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.esmoop.2026.108242_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298128","article-title":"Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution","volume":"19","author":"Kang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.108242_bib34","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"Aran","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108242_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/biom14020168","article-title":"A challenging correlation between tumor cellularity and somatic variant allele fraction in lung and colorectal cancers\u2014specimens of low tumor percentage should be analyzed with caution","volume":"14","author":"Zarabi","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.esmoop.2026.108242_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101706","article-title":"Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)","volume":"35","author":"Menzel","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310497","article-title":"HRD testing of ovarian cancer in routine practice: what are we dealing with?","volume":"24","author":"Kekeeva","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2026.108242_bib38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/PAI.0000000000000684","article-title":"Improved tumor purity metrics in next-generation sequencing for clinical practice: the Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) approach","volume":"27","author":"Patel","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.esmoop.2026.108242_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108242_bib40","doi-asserted-by":"crossref","first-page":"16910","DOI":"10.1073\/pnas.1009843107","article-title":"Allele-specific copy number analysis of tumors","volume":"107","author":"Van Loo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2026.108242_bib41","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108242_bib42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108242_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","article-title":"Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics","volume":"13","author":"Witz","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.esmoop.2026.108242_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrclinonc.2012.48","article-title":"Molecular prescreening to select patient population in early clinical trials","volume":"9","author":"Rod\u00f3n","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/23808993.2016.1238285","article-title":"Molecular screening programmes for precision medicine: lessons learned from personalized medicine trials","volume":"1","author":"Aguilar","year":"2016","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"10.1016\/j.esmoop.2026.108242_bib46","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/PO.19.00398","article-title":"Evolving landscape of molecular prescreening strategies for oncology early clinical trials","volume":"4","author":"Dienstmann","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108242_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.esmoop.2026.108242_bib48","article-title":"GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles","volume":"4","author":"Pozzorini","year":"2023","journal-title":"Cell Rep Med"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108242_bib49","article-title":"A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: evaluation of the analytical performance","volume":"40","author":"Buisson","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:34:20Z","timestamp":1787848460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926021848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926021848"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108242","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homologous recombination deficiency testing implementation in the routine clinical setting: real-life experience and lessons learned","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108242"}}